Candel Therapeutics (NASDAQ:CADL) Insider Francesca Barone Sells 23,447 Shares

Candel Therapeutics, Inc. (NASDAQ:CADL) insider Francesca Barone sold 23,447 shares of the stock in a transaction on Monday, June 29th. The shares were sold at an average price of $10.06, for a total value of $235,876.82. Following the completion of the sale, the insider owned 77,362 shares of the company’s stock, valued at $778,261.72. The trade was a 23.26% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Candel Therapeutics Stock Performance

Shares of CADL stock opened at $9.88 on Thursday. The company has a market capitalization of $723.91 million, a price-to-earnings ratio of -10.08 and a beta of -0.52. Candel Therapeutics, Inc. has a 1-year low of $4.35 and a 1-year high of $11.36. The company has a current ratio of 28.05, a quick ratio of 28.05 and a debt-to-equity ratio of 0.34. The stock’s fifty day simple moving average is $8.24 and its 200-day simple moving average is $6.46.

Candel Therapeutics (NASDAQ:CADL) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.16. On average, sell-side analysts predict that Candel Therapeutics, Inc. will post -0.97 earnings per share for the current fiscal year.

Institutional Trading of Candel Therapeutics

Several large investors have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Candel Therapeutics by 28.5% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,520 shares of the company’s stock worth $109,000 after purchasing an additional 4,772 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Candel Therapeutics by 36.9% during the second quarter. JPMorgan Chase & Co. now owns 19,533 shares of the company’s stock valued at $99,000 after purchasing an additional 5,270 shares during the last quarter. Invesco Ltd. bought a new position in shares of Candel Therapeutics in the first quarter valued at approximately $59,000. Bank of New York Mellon Corp raised its position in shares of Candel Therapeutics by 43.1% in the first quarter. Bank of New York Mellon Corp now owns 136,266 shares of the company’s stock valued at $668,000 after purchasing an additional 41,058 shares during the period. Finally, Janus Henderson Group PLC acquired a new stake in shares of Candel Therapeutics in the first quarter worth $845,000. Institutional investors own 13.93% of the company’s stock.

Analysts Set New Price Targets

CADL has been the topic of a number of research reports. Citigroup dropped their price target on shares of Candel Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a research note on Friday, March 13th. Canaccord Genuity Group reiterated a “buy” rating and set a $25.00 price target on shares of Candel Therapeutics in a report on Friday, March 13th. Cantor Fitzgerald started coverage on Candel Therapeutics in a report on Monday, April 20th. They issued an “overweight” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Candel Therapeutics in a research report on Monday, April 20th. Finally, Wall Street Zen raised shares of Candel Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, June 1st. Six analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Candel Therapeutics has an average rating of “Moderate Buy” and an average price target of $18.00.

Candel Therapeutics Company Profile

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.